JPRN-UMIN000014895已完成未知
Rituximab and methylprednisolone pulse therapy for childhood-onset, complicated, steroid-resistant nephrotic syndrome: a prospective multicenter trial (JSKDC08) - Rituximab and methylprednisolone pulse therapy for childhood-onset, complicated, steroid-resistant nephrotic syndrome: a prospective multicenter trial (JSKDC08)
Japanese Study Group of Kidney Disease in Children0 个研究点目标入组 20 人开始时间: 2014年8月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.History of nephritic-NS, such as IgA nephropathy prior to assignment or in whom secondary NS is suspected. 2.Patients who have been detected gene abnormality(NPHS2,WT1)or in whom gene abnormality(NPHS2,WT1)is suspected. 3.History of receiving rituximab within 1 years prior to assignment. 4.History of receiving any kinds of monoclonal antibody therapy. 5.Having received a new immunosuppressant within 4 weeks prior to assignment. 6.Patients meeting either one of the following infection: 1)Presence or history of severe infections within 6 months prior to assignment. 2)Presence or history of opportunistic infections within 6 months prior to assignment. 3)Presence of active tuberculosis. 4)Patients with a history of tuberculosis or in whom tuberculosis is suspected. 5)Presence or history of active Hepatitis B or Hepatitis C or hepatitis B virus carrier. 6)Presence of HIV infection. 7.Presence or history of angina pectoris, cardiac failure, myocardial infarction, or serious arrhythmia (findings observed under Grade 4 of the CTCAE v4.0-JCOG. 8.Presence or history of auto-immune diseases or vascular purpura. 9.Presence or history of malignant tumor. 10.History of organ transplantation. 11.History of drug allergies to methylprednisolone, acetaminophen, or d-chlorpheniramine maleate. 12.Uncontrollable hypertension. 13.Deteriorated kidney function, e.g. eGFR<45 mL/min./1.73m2. 14.Having received a live vaccine within 4 weeks prior to assignment. 15.Patients showing either one of the following abnormal clinical laboratory value: 1)WBC <3,000/microL. 2)neutrophil <1,500/microL. 3)PLT <50,000/microL. 4)ALT >2.5 x upper limit of normal value. 5)AST >2.5 x upper limit of normal value. 6)Positive for HBsAg, HBsAb, HBcAb and HCVAb. 7)Positive for HIV antibody. 16. Patients who do not agree with contraception during the study period. 17.Women during pregnancy or breast-feeding. 18.Judged inappropriate for this study by the physicians.
研究者
相似试验
进行中（未招募）
不适用
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-SESwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
不适用
A comparison of two different treatments of patients with follicular lymphoma, i.e. the efficacy and tolerability of Rituximab in combination with a new drug (Revlimid) compared to the efficacy and tolerability of Rituximab alone .ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: LLTClassification code 10059432Term: Follicular mixed small and large cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-FISwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
1 期
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.ntreated patients with follicular lymphoma in need of therapy.MedDRA version: 14.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021253-39-DKSwiss Group for Clinical Cancer Research SAKK152
进行中（未招募）
1 期
Comparison of rituximab with lenalidomide or rituximab alone for patients with follicular lymphoma.EUCTR2010-021253-39-ITSAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO152
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS